25 July 2022 - - US-based machine learning-powered generative biology platform developer Generate Biomedicines has named Jason Silvers, M.D., J.D. as the company's chief financial officer, the company said.

Dr. Silvers was at Goldman Sachs for 20 years, where he was named managing director in 2010 and Partner in 2014. Most recently, he was based in London and co-managed healthcare investment banking for Europe, the Middle East and Africa.

Previously, he served as the Global Head of Healthcare Mergers and Acquisitions.

Over his career, he has completed more than 75 merger and acquisition and financing transactions valued at more than USD 400bn.

He graduated magna cum laude from Brown University with a bachelor's of science degree in chemistry. He attended the Johns Hopkins University School of Medicine.

After medical school, he completed one year of a neurosurgical residency at Jackson Memorial Hospital and was awarded the Surgical Intern of the Year distinction.

He continued his education at Yale Law School, where he earned his juris doctor degree and was editor-in-chief of the Yale Journal of Health Policy, Law, and Ethics.

Generative biology represents a fundamental shift in therapeutic development that is driven by machine intelligence.

This new approach leaves traditional trial and error methods of drug discovery behind and is ushering in a new era of programmable drug engineering.

Rather than "discovering" what's observable in the lab, Generate Biomedicines is creating therapeutic opportunities by identifying specific biological processes involved in disease that can be modulated with a wide range of protein modalities.

The promise of generative biology goes beyond existing proteins found in nature and can generate entirely novel, de novo proteins that are purpose-built to address an existing or emerging therapeutic need.

Generative biology will enable therapeutic achievements never before possible, creating entirely new ways to treat all types of diseases, drastically increasing the success rate, and reducing the time required for drug discovery.

Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered multimodality generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities.

Through the seamless integration of computational and wet lab capabilities, Generate's platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates.

The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines.

Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.